Robert Coffin's Insider Trades & SAST Disclosures
Robert Coffin's most recent trade in Replimune Group Inc was a trade of 11,464 Common Stock done at an average price of $6.5 . Disclosure was reported to the exchange on May 16, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Coffin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Replimune Group Inc | Robert Coffin | Director | Sale of securities on an exchange or to another person at price $ 6.47 per share. | 16 May 2024 | 11,464 | 1,821,872 (4%) | 0% | 6.5 | 74,172 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 16 May 2023 | 7,861 | 1,833,336 (5%) | 0% | 18.0 | 141,891 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 67,500 | 67,500 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 45,000 | 1,841,197 (5%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 14.59 per share. | 16 May 2022 | 5,737 | 1,796,197 (4%) | 0% | 14.6 | 83,703 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 39,375 | 39,375 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 26,250 | 1,801,934 (4%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 02 Jul 2021 | 7,810 | 1,775,684 (4%) | 0% | 40.0 | 312,712 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 40.05 per share. | 28 Jun 2021 | 22,826 | 1,783,494 (4%) | 0% | 40.0 | 914,181 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 28 Jun 2021 | 14,663 | 1,806,320 (4%) | 0% | 40.0 | 587,107 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 115,300 | 115,300 | - | - | Employee Stock Option (right to buy) | |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 76,865 | 1,820,983 (4%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 44.87 per share. | 22 Jan 2021 | 30,197 | 1,773,921 (4%) | 0% | 44.9 | 1,354,939 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 43.99 per share. | 22 Jan 2021 | 29,803 | 1,744,118 (4%) | 0% | 44.0 | 1,311,034 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 22 Dec 2020 | 220,000 | 1,804,118 (4%) | 0% | 40.0 | 8,808,800 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 22.32 per share. | 09 Jul 2020 | 145,500 | 2,048,368 (5%) | 0% | 22.3 | 3,247,560 | Common Stock |
| Replimune Group Inc | Robert Coffin | Director, President & Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 21.02 per share. | 09 Jul 2020 | 24,250 | 2,024,118 (5%) | 0% | 21.0 | 509,735 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges